Skeletal muscle is responsible for the majority of glucose disposal in the body.
Introduction
AKT, also known as protein kinase B (PKB) (1) , is a serine/threonine kinase that plays a key role in insulin-stimulated glucose uptake (2) . There are three isoforms of AKT family, AKT1/PKBα, AKT2/PKBβ and AKT3/PKBγ. The three AKTs are highly related to each other in both structure and amino acid sequence (~85%) and are activated by phosphatidylinositol-3 kinase (3) . The function of individual isoforms of AKT in skeletal muscle has been recognized by an increasing number of studies. Previous studies comparing the three proteins support the notion that these isoforms have similar biochemical characteristics (4) . However, recent studies prove that the three isoforms of AKT exhibit tissue-specific expression and distinct functions. In mice, AKT1 loss of function causes diminished fetal growth but maintain normal glucose regulation (5) . AKT2 deficiency results in insulin resistance and a type 2 diabetes mellitus-like syndrome (6) , and global knockout of AKT3 leads to reduced brain size (7) . It is well documented that loss of AKT2 is associated with metabolic disorder with glucose imbalance, growth deficiency (8, 9) , loss of adipose tissue (10) , but the mechanisms behind are not fully understood. Importantly, scarce knowledge is available regarding the alterations on regulatory mechanisms and molecular changes induced by AKT2 deficiency in skeletal muscle, an active metabolic tissue that depends mainly on glucose as energy resource, and also a major site of insulin-stimulated glucose uptake.
After extensive proliferation, myoblasts undergo differentiation and fusion with each other or existing myofibers to build functional muscle tissue (11) . Many transcription factors are involved in the control of myogenesis. Members of the MyoD family play important roles in the control of muscle differentiation during embryonic development and adult muscle regeneration (11) . The myogenic activity of these transcriptional factors is enhanced through their interaction with the myocyte enhancer factor 2 (MEF2) family (11) . In vertebrates, the MEF2 family includes four members, MEF2A, B, C and D, which share high sequence homology in their DNA binding and dimerization domains but are divergent in their C-terminal transcriptional activation domains (11) . The MEF2 isoforms active in skeletal muscle are A, C and D (12) . Skeletal muscle-specific deletion of MEF2C results in neonatal morality due to defects in muscle integrity and failure in sarcomere formation (13, 14) . Moreover, combined deletion of the MEFA, C and D results in a blockade to generation, suggesting essential roles of MEF2A, C and D in satellite cell differentiation (11) . It is reported that loss of AKT2 results in growth deficiency by exhibiting decreased body weight (15-17), and impaired myotube maturation in the skeletal muscle (18). However, the impact of AKT2 deficiency in muscle development and the possible implication of MEF2 transcription factors-dependent signaling has not been previously investigated.
Skeletal muscle is responsible for the majority of glucose disposal in the body. Impaired glucose handling capacity leads to a state of insulin resistance (19). Insulin resistance in the skeletal muscle accounts for 85-90% of the impairment of total body glucose disposal in patients with tye 2 diabetes (T2D) (20). AKT2-null mice exhibited insulin resistance with elevated plasma triglycerides (15) and AKT2 is essential for insulin-stimulated glucose uptake which cannot be replaced by AKT1 in mouse skeletal muscle (2) . Interestingly, reduced AKT2 expression and impaired insulin-stimulated AKT2 activation are reported to occur in diabetic (21) and insulin resistant (22) human skeletal muscle. Thus, these researches suggest that AKT2 plays an important role in systemic glucose homeostasis.
AMP-activated protein kinase (AMPK) is a major regulator of energy substrate use in several organs. Responding to high AMP/ATP and ADP/ATP ratios, AMPK activation leads to enhanced fatty acid oxidation, thus influencing energy homeostasis (23). In addition, AMPK activation has been shown to promote the translocation of GLUT4 to the plasma membrane, thus stimulating glucose uptake in skeletal muscle (24-26). Furthermore, chronic activation of AMPK reduces markers of skeletal muscle fragility (27) and enhances muscle fiber oxidation capacity by stimulating mitochondrial biogenesis (28-30). It has been published that AKT1 negatively regulates phosphorylation of AMPK in the myocardium and MEFs (31, 32).
Additionally, it is reported that MEF2A is activated in response to AMPK activation in skeletal muscle (33). However, whether AKT2 functions as regulator of AMPK and the regulatory signaling pathway in normoxic skeletal muscle remains to be investigated.
We observed that AKT2 KO mice exhibited decreased body weight compared to their age-and gender-matched WT mice. Despite obvious loss of white adipose tissue as previously reported (2, 15, 34) , we also found that the lean mass of AKT2 KO mice decreased significantly. These data indicate an important role for AKT2 in skeletal muscle development. Therefore, we hypothesized that AKT2 deficiency causes deficits in skeletal muscle development, which leads to the alteration of skeletal muscle reprogramming in development and growth. To test this, we analyzed the expression of molecules related to skeletal muscle development, glucose uptake and metabolism at both young (3 months) and old (8 months) mice. We found that upon AMPK activity and MEF2A were downregulated in young AKT2 KO mice, and this downregulation was prevented by AMPK activation. We also observed that mitochondrial biogenesis and oxidative capacity were impaired in the skeletal muscle of AKT2 deficient mice. In addition, AKT2 KO mice exhibited much deteriorated insulin resistance after high-fat-diet (HFD) feeding. Our results indicate that AKT2 is an important factor for AMPK activation and mitochondrial biogenesis in the skeletal muscle, and thus establish a new important function of AKT2 in the development and glucose metabolism of skeletal muscle.
Results

Disturbance of glucose metabolism due to AKT2 deficiency
To investigate the impact of AKT2 deficiency on growth, body mass of mice at different ages was recorded. AKT2 KO mice were born healthy, and were able to grow to adulthood without abnormalities of lifespan, as previously described by other groups (35). However, AKT2 KO mice showed a reduction in body weight beginning around postnatal day 40 (Fig. 1A) , and from P90, the AKT2 KO mice were visibly distinguishable from their WT littermates ( Fig. 1B) , although there were no differences of tibial length between WT and AKT2 KO mice (suppl. Fig.1 ), nor in the daily food intake ( Fig. 1C and D).
Since AKT2 functions downstream of PI3K which mediates insulin-induced effects on glucose metabolism (6, 15, 36) , we investigated whether glucose metabolism was also affected due to AKT2 deficiency by evaluating global glucose metabolic status. AKT2 KO mice exhibited impaired glucose tolerance at 3 and 8 months of age ( Fig. 1E and F; suppl. Fig. 2 ). Interestingly, glucose intolerance was less pronounced in female AKT2 KO mice compared to age-matched male mice (suppl. Fig.2 ). Insulin sensitivity was also impaired in AKT2 KO at 3 and 8 months of age ( Fig.   1G and H). Plasma insulin levels and HOMA-IR were elevated in AKT2 KO mice at 3 and 8 months of age ( Fig. 1I and J). These results suggest that AKT2 deficiency in skeletal muscle impairs both the response of glucose tolerance and insulin sensitivity.
Tissue and age-related changes in AKT2 expression
Next we explored AKT2 expression in different tissues. AKT2 mRNA and protein were enriched in tissues highly associated with glucose metabolism including pancreas, liver, brain and soleus muscle ( Fig. 2A and B ). To further investigate the expression pattern of AKT2 in skeletal muscle during development, AKT2 protein expression in soleus muscle of mice at different ages was evaluated. We observed a determinant of its function, and mitochondria play a central role in oxidative metabolism. The high levels of AKT2 expression in metabolically active organs and the link with AMPK signaling pointed to a previously unappreciated effect of AKT2 in mitochondrial function and metabolism. Therefore, we sought to determine whether relevant mitochondrial parameters were altered in skeletal muscle deficient for AKT2.
Electron microscopy revealed no gross morphological changes of mitochondria (suppl. Fig. 5 ). We also quantified mitochondrial DNA (mtDNA)/genomic DNA, and the result showed diminished mtDNA copies in the 8-month-old AKT2 KO mouse muscle ( Fig. 5A and B ). Peroxisome proliferator activated receptor gamma coactivator 1 alpha (PGC-1α), mitochondrial transcription factor A (MTFA), NRF1 and Endonuclease G (EndoG) are recognized as regulators of mitochondrial function and biogenesis (38) (39) (40) (41) (42) . Our results showed that AKT2 deficiency results in decreased expression of pgc-1α, mtfa, nrf-1 and pparα in the skeletal muscle deficient for AKT2 both at the transcript ( Fig. 5C ) and protein ( Fig. 5D ) levels, suggesting that impaired mitochondrial biogenesis and function due to AKT2 deficiency.
Disturbance of glucose uptake and usage in skeletal muscle of AKT2 KO mice
In healthy subjects, skeletal muscle is responsible for consuming nearly 80% of insulin-stimulated glucose uptake (43) , suggesting that the skeletal muscle is a major regulator of glucose metabolism. In skeletal muscle, the insulin-stimulated glucose uptake is performed by GLUT4, which rapidly translocated to the plasma membrane in response to insulin stimulation (44) . Since AKT2 KO mice exhibited hyperglycemia at an early stage of life, we decided to explore whether there were defects on glucose uptake in the muscle and analyzed GLUT4 expression in this tissue. Our result showed that GLUT4 protein abundance was significantly decreased in soleus muscle of AKT2 KO mice at the age of 3 and 8 months ( Fig. 6A , C, D and F). We next evaluated the activity of glycogen synthase kinase 3 beta (GSK3β), a serine/threonine kinase essential for the regulation of glycogen synthesis (45). Our result showed that, in addition to markedly reduced GLUT4 expression, GSK3β phosphorylation (p-GSK3β) was increased by 30% in 3-month-old AKT2 KO skeletal muscle compared to WT ( Fig.   6A , B, D and E). Interestingly, at the age of 8 months, p-GSK3β in skeletal muscle of AKT2 KO mice increased as much as 20% compared to WT ( Fig. 6B and E). To verify the regulation of GLUT4 by AKT2, GLUT4 was checked in C2C12 cells transfected with NC or siAKT2. The result showed that GLUT4 expression decreased at both protein and mRNA level after AKT2 knockdown ( Fig. 6 G-I), suggesting that AKT2 positively regulates GLUT4 expression in skeletal muscle.
To check the amount of glycogen stored in skeletal muscle of AKT2 KO mice, glycogen quantification and staining were performed in both genotypes of 3-and 8-month old mice. The results showed that the glycogen quantity was identical in soleus muscle of WT and AKT2 KO younger mice, but there was an increase of glycogen content in the skeletal muscle of AKT2-deficient 8-month-old mice ( Fig.   6J -L). These data suggest that, on one hand AKT2 deficiency accounts for decreased glucose uptake and disturbance of carbohydrate metabolism in skeletal muscle, which may be a main cause of increased blood glucose. On the other hand, increased expression of p-GSK3β and glycogen content in AKT2 KO adult but not young mice suggest that altered glycogen metabolism is a secondary effect due to AKT2 loss-of-function.
Improvement of global and skeletal muscle metabolism by AMPK activator in AKT2-null mice
To check the potential role of AMPK in AKT2 deficiency-induced skeletal muscle sarcopenia, changes in glucose uptake, insulin resistance and mitochondrial biogenesis, an AMPK activator, AICAR, was continuously injected in AKT2 KO or WT mice for 4 weeks. Glucose and insulin tolerance assays were performed at the end of AICAR treatment. The results showed that AKT2 KO mice treated with AICAR had significantly improved insulin tolerance compared to untreated mice ( Fig. 7A and B ), without affecting body weight ( Fig. 7C ). Furthermore, as an indication of AMPK activity, we measured phospho-ACC (p-ACC) levels in soleus muscle and found that p-ACC increased two-fold post-AICAR treatment (Fig. 7D) . To investigate the possible activation of the MEF2 signaling pathway by AMPK, we assessed the expression of MEF2A, MEF2D and factors related to glucose metabolism and mitochondrial biogenesis in this setting. The results showed that expression of MEF2A was significantly induced by AICAR treatment compared to saline-treated controls (Fig.   7D ). Moreover, phosphorylation of GSK3β, which was highly stimulated in AKT2-deficient samples, was normalized by AICAR infusion (Fig. 7D ). In addition, there was also significant elevation of NRF-1, PPARα, and EndoG protein abundance ( Fig. 7D ). Therefore, our data suggest that the decrease of MEF2A, as well as molecules involved in glucose metabolism and mitochondrial biogensis in skeletal muscle deficient for AKT2 is due to AMPK inactivation, which may in turn contribute to aggravate insulin resistance and to impair glucose tolerance in serum.
Upregulation of AKT2 activity in skeletal muscle with insulin resistance
To investigate the function of AKT2 on global metabolic homeostasis, WT and AKT2 KO mice were fed high fat diet (HFD; see methods for composition), for 12 weeks. At the end of this period, mice of the four groups were submitted to glucose tolerance test and insulin tolerance test. AKT2 KO mice with regular chow exhibited insulin resistance and decreased glucose tolerance ( Fig. 8A and B ). HFD feeding induced impaired glucose tolerance in both genotypes at almost the same extent ( Fig.   8A and B). However, although WT mice showed insulin resistance after HFD feeding for 12 weeks, HFD induces much greater impairment of insulin resistance in AKT2 KO mice ( Fig. 8C and D) . Serum insulin was also highly induced in AKT2 KO mice with HFD treatment (Fig. 8E and F) . Therefore, our results suggest that AKT2 plays a key role in maintaining metabolic homeostasis of glucose and proper insulin response during HFD-induced obesity. We then compared the expression of p-AKT2, AKT2, p-AMPK and AMPK in the soleus muscle of WT mice fed normal diet (Vehicle) or HFD.
The result showed that compared to the skeletal muscle from Vehicle group, the skeletal muscle of HFD-treated mice exhibited increased p-AKT2 protein and decreased total AKT2 protein abundance, and p-AMPK decreased in soleus muscle of mice with treated HFD (Fig. 8G) . These data indicate that during the development of obesity and insulin resistance caused by diet, increased p-AKT2/AKT2 ratio may be accused for glucose metabolic disorder in skeletal muscle.
Discussion
Multiple lines of evidence support the hypothesis that AKT2 is involved in growth and glucose metabolism (2, 6, 46) . In this study, we provide evidence that AKT2 positively regulates AMPK activation, which play an important role in the control of growth, mitochondrial biogenesis and function of skeletal muscle. We found that p-AMPK, MEF2A, and molecules associated with mitochondrial biogenesis and function were downregulated in skeletal muscle of AKT2 KO mice, which can be reversed by AMPK activator. We also observed that AKT2 regulates GLUT4 expression in an AMPK-independent manner in skeletal muscle. Moreover, disturbed glucose metabolism was more severe in AKT2 KO-HFD mice, and activation of AKT2 activity was observed in WT mice with HFD-induced obesity. Our results indicate that AKT2 is involved in AMPK activation which in turn regulates skeletal muscle development.
We also proved that AKT2 participates in mitochondrial biogenesis and glucose metabolism at normoxic skeletal muscle. Therefore, our study establishes a new and important role for AKT2 in the developmental and metabolic regulation of glucose in skeletal muscle.
AKT1 and AKT2 KO mice exhibit remarkably different phenotypes (5, (47) (48) (49) ), suggesting that the two isoforms regulate a subset of unique downstream genes and biological functions respectively. First, we checked AKT2 expression in different tissues of mice, the results showed that AKT2 is most abundant in organs that are active for glucose metabolism. We further found elevated p-AKT2 protein expression in soleus muscle at different ages. This result was also verified in vitro by checking different days of differentiation in C2C12 cells, indicating important role of AKT2 during skeletal muscle development. In AKT2 KO mice, there was no difference of AKT1 protein abundance compared to WT, suggesting the unique function of AKT2 in skeletal muscle, which is not compensated by other AKT isoforms.
In AKT2 KO mice, we observed constant mild decrease of body weight since the age of 1-month-old and throughout the life, which is in agreement with other research (15, 17). Since most research reported that the loss of body weight in AKT2 KO mice is largely due to decreased white adipose tissue (WAT), few focused on the alteration of skeletal muscle. Therefore, to investigate whether there was impact of AKT2 loss-of-function on skeletal muscle development, we first weighed the lean mass of both genotypes, and observed a significant decrease in AKT2 KO mice.
Further assessment showed decreased weight of hindlimb muscles, while the tibial length was equivalent in both genotypes, suggesting the decreased body mass is partly due to the loss of skeletal muscle despite WAT. Our further investigation of soleus muscle showed diminished cross-sectional area, and electromicroscopic images exhibited smaller sarcomeres of AKT2 KO mice. Thus, our data suggests impaired skeletal muscle development due to AKT2 deficiency.
To explore the mechanism involved in the regulation of skeletal development by AKT2, we focused on the MEF2 family, which is accepted as a key transcriptional factor during muscle differentiation and development (11, 50, 51) . We observed that protein abundance of MEF2A was significantly suppressed in skeletal muscle of AKT2 KO mice at both 3-month and 8-month old. Despite the important role of MEF2 family in skeletal muscle development, it is also known as a regulator of muscle energy metabolism (52, 53). It is reported that MEF2A can be activated by AMPK in skeletal muscle (37, 54) . To explore if there is involvement of AMPK in AKT2-related MEF2A expression, AMPK activation was evaluated in skeletal muscle. Our results showed that p-AMPK was significantly decreased in skeletal muscle of AKT2 KO mice either at the age of 3-or 8-months old. To verify the decreased AMPK phosphorylation is a direct effect of AKT2 deficiency but not an indirect feedback, p-AMPK expression was checked in C2C12 cells transfecting with siAKT2. Our data showed that p-AMPK protein abundance decreased significantly when AKT2 was knocked down in C2C12 cells, while AKT1 expression remained unchanged during the treatment. Therefore, our results suggest that AKT2 positively regulates AMPK activity at normal conditions in skeletal muscle. To further investigate the mechanisms underlying the role of AKT2 in skeletal muscle development, AKT2 KO mice were treated with AICAR injection for 4 weeks. The result showed that after AICAR treatment, AKT2 KO mice developed greatly alleviated insulin resistance; in addition, MEF2A was significantly induced in soleus muscle of AKT2 KO mice. Thus, these results further confirmed that AKT2 regulates skeletal muscle development via AMPK activation.
Skeletal muscle, which accounts for 40% of body mass, is the major site of insulin-stimulated glucose uptake, with the majority of glucose that enters muscle fibers in response to insulin being stored as glycogen, and plays a key role in type 2 diabetes (55-57). Lack of AKT2 in skeletal muscle decreased both the insulin sensitivity and responsiveness of glucose transport (15). Our results of AKT2 KO and WT mice were in agreement with these reports. However, recently it has been reported that AKT2 deficiency in skeletal muscle is not sufficient to affect development and glucose metabolism of skeletal muscle (58) . One possible explanation for the discrepancy could be that, during the research, the authors used young mice at ages between 8-12 weeks. As we show in the present work, AKT2 KO mice did not show significant decrease of body weight and glucose tolerance until 3-month of age. Therefore, we speculate that the lack of direct effects of AKT deletion in skeletal muscle reported in by Jaiswal N et al., may be related to the age of the mice. Our study also proved that AKT2 deficiency increased insulin resistance and hyperinsulinemia compared to WT during HFD-induced obesity, without obvious changes of islets. The protein expression of GLUT4 decreased in adipose tissue of obese and insulin resistant subjects (59, 60) . However, the regulation of GLUT4 expression in skeletal muscle has not been well documented. Our data showed decreased GLUT4 expression in soleus muscle deficient for AKT2 as well as in C2C12 cells with AKT2 knockdown, indicating decreased glucose uptake into skeletal muscle cell, which may be a reason for impaired glucose tolerance and insulin resistance. In addition, there was no alteration of GLUT4 protein expression upon the stimulation of AMPK activator, suggesting a direct regulation of GLUT4 by AKT2. Therefore, these results suggest that AKT2 plays a key role in glucose homeostasis in skeletal muscle.
PPARα plays a central role in the regulation of muscle fuel preferences. Its expression also parallels the oxidative capacity of muscle fibers (61, 62) . Therefore, our data confirmed the conclusion that AKT2 deficiency impairs mitochondrial biogenesis, which in turn causes glycogen accumulation due to decreased glucose oxidation. Notably, there is research proved that AKT2 deficiency did not cause alteration of p-AMPK or GLUT4 expression in muscle (63) . However, the background of mice strain, also the gender and age of mice may cause the differences, as we showed that female mice exhibited delayed and alleviated glucose intolerance.
Finally, to testify whether the phenomenon of sarcopenia and glucose metabolic disorder was caused via AKT2-AMPK signaling, by applying AICAR to AKT2 KO mice, these mice exhibited ameliorated glucose tolerance and insulin resistance, and expression of proteins related to muscle development and mitochondrial biogenesis increased to normal level, suggesting AMPK is a key mediator during AKT2-associated regulation of skeletal muscle metabolism. In consistent with this result, we observed decreased total AKT2 protein abundance and increased p-AKT2 expression in soleus muscle of mice treated with HFD for 12 weeks, which exhibited glucose intolerance and insulin resistance. These data strengthened our conclusion that AKT2 and its activity plays a key role in glucose metabolism of skeletal muscle.
In summary, our study demonstrated an obligatory role of AKT2 in development and glucose metabolism of skeletal muscle. Our results showed that although AKT2 deficiency is not lethal to life, however, its deficiency impairs systemic glucose metabolism. Moreover, AMPK phosphorylation promotes the transcription of molecules associated with skeletal muscle development and mitochondrial biogenesis. Our study gives new sights into the mechanism relating insulin resistance and sarcopenia of skeletal muscle in T2D, suggesting that AKT2 may be a key target for the therapy.
Methods
Animals
The AKT2 knockout (AKT2 KO) mouse line with C57/BL6 background was used in experiments. For all experiments, mice between 3 and 8 months old were used. The mice were maintained on a 12:12 h light/dark cycle, with controlled temperature (22 +/− 2 ℃) and humidity (55 +/− 5%) conditions. The mice received ad libitum access to water and standard lab chow, unless otherwise specified.
Glucose tolerance test and insulin tolerance test
Glucose tolerance and insulin tolerance were investigated in AKT2 KO and WT mice . Briefly, AKT2 KO and WT mice were initially divided into a 3 and 8 months old group. For the glucose tolerance test (GTT), overnight-fasted male mice were intraperitoneally injected with glucose (2 g glucose/kg), and the glucose level was measured at 0、5、15、30、60、120 min. For the insulin tolerance test (ITT), insulin was intraperitoneally administered to male mice (fasting for 6 h) at 1 unit/kg, and glucose levels were monitored using blood collected from a tail vein with an Accu-Chek Performa glucometer (Roche, Basel, Switzerland). HOMA of insulin resistance (HOMA-IR) is calculated as follows: HOMA-IR=FINS/22.5e-InFPG (FINS: fasting serum insulin; FPG: fasting plasma glucose ) WT and AKT2 KO mice were fed ND or HFD for 12 weeks, glucose tolerance and insulin tolerance were evaluated at the end of 12-week feeding with ND or HFD (n=6 for both treatment). (E) Serum insulin concentration of mice with different treatment and (F) HOMA-IR calculation (n=4-9). (G) Representative immunoblots of p-AKT2, AKT2, p-AMPK and AMPK in skeletal muscle from mice fed ND or HFD for 12 weeks (n=4 for both treatment). *P < 0.05; **P < 0.01; ***P < 0.001, WT versus KO. Statistical significance was determined using two-way ANOVA followed by Bonferroni post-test. During muscle development, AKT2 promotes GLUT4 expression, which transports glucose from blood into muscle cells. AKT2 also increases AMPK phosphorylation, which promotes the expression of MEF2A that positively regulate skeletal muscle development. However, when AKT2 is phosphorylated by stimulations such as high-fat diet (HFD), it has the opposite function. On the other hand, activated AMPK promotes expression of genes related to mitochondrial biogenesis, including PPARα, PGC-1α, NRF-1 and EndoG. p-AMPK also inhibits phosphorylation of GSK3β upon AKT2 regulation, therefore increases glycogen synthesis in skeletal muscle cells. 
Peritoneal injection of AICAR
